It was reported yesterday that the US Food and Drug Administration (USFDA) has granted breakthrough therapy designation to United States-based Celgene's Pomalyst (pomalidomide) intended for the treatment of HIV.
The designation has been granted for the product to treat patients with HIV-positive Kaposi sarcoma who have earlier received systemic chemotherapy, in addition to patients with HIV-negative Kaposi's sarcoma.
Pomalyst is one of the firm's IMiD agents for the treatment of some blood cancers. It is a thalidomide analogue indicated, in combination with dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies including lenalidomide and proteasome inhibitor.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT